Corporate Investor

Updated:

BGI Genomics Technology

BGI Genomics Technology began in 1999 under Wang Jian, who also chairs BGI Group. Wang Shi, founder of China Vanke, serves as co-chairman. The firm...

BGI Genomics Technology logo

BGI Genomics Technology

BGI Genomics Technology began in 1999 under Wang Jian, who also chairs BGI Group. Wang Shi, founder of China Vanke, serves as co-chairman. The firm concentrates on genomics testing and research through its ownership stake in BGI Genomics. Investment activity centers on direct partnerships and joint ventures. A $50M collaboration with Natera covers oncology and reproductive health testing. Perennial Holdings participates in the BGI Perennial Genomics Diagnostic Imaging Centre. Geographic reach includes operations in China and the United States via Complete Genomics in Mountain View, California. Team size and total deployment remain undisclosed. The firm maintains BGI Health Foundation and Mammoth Foundation as separate philanthropic vehicles. Leadership holds roles in the Genetics Society of China and Chinese Society of Biotechnology.

General information

Firm type

Corporate Investor

Year founded

1999

AUM

Undisclosed

Location

Region

Asia

Country

China

City

Shenzhen

Corporate office

Shenzhen, China

Principals

Wang Jian

Co-founder and Chairman of BGI Group and BGI Genomics

Sector focus

Digital Health

Frequently asked questions

Who runs investment decisions at BGI Genomics Technology?

Wang Jian serves as co-founder and chairman. Decisions align with the firm's role as controlling shareholder of BGI Genomics and its partnership agreements.

Does BGI Genomics Technology participate in fund commitments or only direct deals?

Activity centers on direct partnerships and joint ventures, including the Natera collaboration and Perennial Holdings venture.

Where does the underlying wealth come from?

The firm operates as a corporate investor tied to BGI Group genomics operations rather than family wealth.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Shenzhen Corporate Investor profiles